| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc7693dae06e6b3ff39c820ec91bf5db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee602c630e57f59c6cfc1c1634e36064 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1777
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2015-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_260ceb2d831f3a829b19720a34682072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87ebd6df563b73b26d703d4bf5384b25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a968ee502bd21aa8c7bc49e7c1688c0b |
| publicationDate |
2017-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9592269-B2 |
| titleOfInvention |
Compounds and methods of modulating angiogenesis |
| abstract |
A pharmaceutical composition includes a synthetic peptide consisting of about 10 to about 50 amino acids and having an amino acid sequence substantially homologous to consecutive amino acids of a portion of the cytoplasmic domain of at least one of α v β 3 integrin or VEGFR2 that includes a tyrosine residue, the amino acid sequence of the peptide including a phosphorylated tyrosine residue or a γ-carboxyglutamic acid residue that is substituted for a corresponding tyrosine residue of the portion of the cytoplasmic domain of α v β 3 integrin or VEGFR2. |
| priorityDate |
2011-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |